Graves Orbitopathy

• CLINICAL_TRIALS research · 2026-04-23
  Clinical Trial Update: Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease [Phase 2]

  Phase 2 clinical trial update on tofacitinib for glucocorticoid-resistant moderate-to-severe Thyroid Eye Disease; the study is currently act…

• CLINICAL_TRIALS research · 2026-03-16
  Clinical Trial Update: Development of a Non-Invasive Prognostic Test for Graves Orbitopathy [NA]

  Clinical trial update describing the development of a non-invasive prognostic test for Graves' orbitopathy, sponsored by University Hospital…

• CLINICAL_TRIALS research · 2025-08-15
  Clinical Trial Update: Describe the Progression of Inflammatory Orbitopathy and the Biological Progression of Patients Receiving Second-line Treatment

  This recruiting clinical trial studies the progression of inflammatory orbitopathy (Graves' orbitopathy) and the biological progression of p…

• CLINICAL_TRIALS research · 2025-01-29
  Clinical Trial Update: A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) [Phase 2, Phase 3]

  This document notes an ongoing Phase 2b/Phase 3 trial evaluating linsitinib for Thyroid Eye Disease, currently active but not recruiting.

• CLINICAL_TRIALS research · 2024-06-20
  Clinical Trial Update: Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease

  Amgen's expanded access protocol for Teprotumumab (HZN-001) to treat active thyroid eye disease (Graves' orbitopathy) has been updated; the …

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS research · 2013-12-10
  Clinical Trial Update: Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy [Phase 2, Phase 3]

  A clinical trial update about a Phase 2/Phase 3 study comparing prednisone to doxycycline for Graves' orbitopathy (thyroid-associated ophtha…